Minimal change disease: an unusual presentation of marginal zone MALT lymphoma.

TitleMinimal change disease: an unusual presentation of marginal zone MALT lymphoma.
Publication TypeJournal Article
Year of Publication2016
AuthorsInayat F, Law JK, Myers-Gurevitch PM, Seshan SV, Perlman AS
JournalClin Nephrol
Volume85
Issue3
Pagination184-8
Date Published2016 Mar
ISSN0301-0430
KeywordsAdenocarcinoma, Aged, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic Combined Chemotherapy Protocols, Bendamustine Hydrochloride, Colonic Neoplasms, Diagnosis, Differential, Humans, Lymphoma, B-Cell, Marginal Zone, Male, Neoplasm Recurrence, Local, Neoplasms, Second Primary, Nephrosis, Lipoid, Proteinuria, Rituximab
Abstract

Minimal change disease (MCD) in association with low-grade extra-nodal marginal zone B-cell lymphoma (MZL) of mucosa-associated lymphoid tissue (MALT) (MALT lymphoma) is a rare clinicopathologic entity. We report a 68-year-old male who presented with nephrotic range proteinuria as the first manifestation of underlying MZL, confirmed with standard set of investigations. Being a steroid non-responder, he was treated with rituximab demonstrating a marked response with resolution of proteinuria. However, he relapsed after 3 months. Upon relapse, a combination of rituximab and bendamustine (R-Benda) was initiated achieving sustained resolution of proteinuria. No additional treatment was administered and the proteinuria has remained in remission for over a year.

DOI10.5414/CN108593
Alternate JournalClin Nephrol
PubMed ID26636329
Related Faculty: 
Surya V. Seshan, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700